TCL Archive FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint. July 21, 2006
TCL Archive Olaparib, A PARP Inhibitor, Can Reduce Tumor Size In Advanced Ovarian Cancer August 27, 2010
TCL Archive FDA Reaction to DCT Proposals ‘Positive,’ But Chabner, Wittes ‘Disappointed’ In That Response June 17, 1988
TCL Archive FDA Advisors Recommend Approval Of Taxol for Node-Positive Breast Cancer September 24, 1999
TCL Archive House Bill Gives NCI $135 Million Increase, NIH $846 Million for FY 1988 Over 1987 Budgets August 7, 1987
